Drug Trial Radar · NCT06212648
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
253
Actual
Start
Mar 25, 2022
Primary completion
Nov 27, 2022
Study completion Jan 27, 2023
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential hypertension.
Conditions
- Hypertension
- Essential Hypertension
Interventions
SPC1001 HighDrug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid1Drug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 Mid2Drug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC1001 LowDrug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC3001Drug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4001Drug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
SPC4002Drug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
PlaceboDrug
Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MSSBP measures the amount of change after 8 weeks from baselineTime frame: 8 weeks from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHA Gangnam Medical Center, CHA University
Seoul, Gangnam, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.